461031-79-8

Basic information

• Product Name: 4-(benzyloxy)-2,6-dichlorobenzaldehyde
• Synonyms: 4-(benzyloxy)-2,6-dichlorobenzaldehyde
• CAS NO: 461031-79-8
• Molecular Weight: 281.138
• Mol File: 461031-79-8.mol
• Article Data: 13

Chemical Properties

• CAS DataBase Reference: 4-(benzyloxy)-2,6-dichlorobenzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(benzyloxy)-2,6-dichlorobenzaldehyde(461031-79-8)
• EPA Substance Registry System: 4-(benzyloxy)-2,6-dichlorobenzaldehyde(461031-79-8)

Safety Data

• Hazardous Substances Data: 461031-79-8(Hazardous Substances Data)

Upstream product

• 4397-53-9 p-benzyloxybenzaldehyde 
• 60964-09-2 2,6-dichloro-4-hydroxybenzaldehyde 
• 126663-61-4 1-<(tert-butyldimethylsilyl)oxy>-3,5-dichlorobenzene 
• 591-35-5 3,5-dichlorophenol 
• 100-39-0 benzyl bromide 
• 82772-93-8 2,6-dichloro-4-methoxy-benzaldehyde 

Downstream Products

• 461031-80-1 4-benzyloxy-2,6-dichlorostyrene 
• 86111-47-9 (2,6-dichloro-4-methoxy-phenyl)-methanol 
• 461031-82-3 (1S)-1-[4-(benzyloxy)-2,6-dichlorophenyl]-2-(tert-butyldimethylsilyl)oxy-1-ethylalcohol 
• 886616-15-5 (2,6-dichloro-4-benzyloxy-phenyl)-methanol 
• 886616-14-4 5-benzyloxy-2-bromomethyl-1,3-dichloro-benzene 
• 956122-77-3 2-(4-benzyloxy-2,6-dichloro-benzyl)-2-aza-spiro[4.5]decan-1-one 
• 956122-81-9 trifluoro-methanesulfonic acid 3,5-dichloro-4-(1-oxo-2-aza-spiro[4.5]dec-2-ylmethyl)-phenyl ester 
• 956125-89-6 (R)-4-((R)-benzyl-2-oxo-oxazolidin-3-yl)-3-(4-methoxy-2,6-dichloro-benzyl)-4-oxo-butyraldehyde 
• 956125-88-5 (R)-4-benzyl-3-[(S)-2-(4-methoxy-2,6-dichloro-benzyl)-pent-4-enoyl]-oxazolidin-2-one 
• 94278-70-3 2-(bromomethyl)-1,3-dichloro-5-methoxybenzene 

Relevant articles and documents

NOVEL THYROMIMETICS

Compounds are provided having the structure of Formula (I) or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein R1, R2, X1, X2, Y1, and Y2 are as defined herein. Such compounds function as thyromimetics and have utility for treating diseases such as neurodegenerative disorders and fibrotic diseases. Pharmaceutical compositions containing such compounds are also provided, as are methods of their use and preparation.

CYCLOHEXYLPYRAZOLE-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1

The present invention discloses novel compounds of Formula (I): having 11β-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compound

CYCLOHEXYL SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1

The present invention discloses novel compounds of Formula I: having 11β -HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11β-HSD type 1 activity.